Cargando…
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
BACKGROUND: Increasing availability and use of long-acting injectable antipsychotics have generated a need to compare these formulations with their oral equivalents; however, a paucity of relevant data is available. METHODS: This post hoc comparison of the long-term efficacy, safety and tolerability...
Autores principales: | Markowitz, Michael, Fu, Dong-Jing, Levitan, Bennett, Gopal, Srihari, Turkoz, Ibrahim, Alphs, Larry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722005/ https://www.ncbi.nlm.nih.gov/pubmed/23845018 http://dx.doi.org/10.1186/1744-859X-12-22 |
Ejemplares similares
-
Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016) -
PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016) -
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder
por: Fu, Dong-Jing, et al.
Publicado: (2016) -
Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011) -
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa, Jennifer Kern, et al.
Publicado: (2012)